Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q.
Wu H, et al. Among authors: liu j, liu s, liu q.
Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. Epub 2015 Jul 3.
Leukemia. 2016.
PMID: 26139428
Free PMC article.
No abstract available.